NCT05000151 (ProprioRespi) is a clinical trial in Hypermobile Ehlers-Danlos Syndrome, sponsored by Hakimi Adrien.

Who is sponsoring NCT05000151?

NCT05000151 is sponsored by Hakimi Adrien.

What condition does NCT05000151 study?

NCT05000151 studies Hypermobile Ehlers-Danlos Syndrome.

Is NCT05000151 still recruiting?

NCT05000151 is currently completed. Last updated 22 July 2022.

Last reviewed 2022-07-22 · How we verify

NCT05000151: ProprioRespi

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lung Volume Perception and Impact of a Cognitive Task on Ventilation in Hypermobile Ehlers-Danlos Syndrome.

Completed Last updated 22 July 2022

What this trial tests

trial in Hypermobile Ehlers-Danlos Syndrome in 38 participants. Completed in 19 May 2022.

Timeline

2 September 2021

Primary endpoint
19 May 2022

19 May 2022

Quick facts

Lead sponsor	Hakimi Adrien
Status	Completed
Study type	OBSERVATIONAL
Enrollment	38
Start date	2 September 2021
Primary completion	19 May 2022
Estimated completion	19 May 2022
Sites	1 location across France

Conditions studied

Hypermobile Ehlers-Danlos Syndrome — all drugs for Hypermobile Ehlers-Danlos Syndrome →

Sponsor

Hakimi Adrien

Who can join

18 and older, any sex, with Hypermobile Ehlers-Danlos Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with hypermobile Ehlers-Danlos syndrome have respiratory and proprioceptive disorders. The aim of this study is to explore whether there is an alteration in lung volume perception in patients with hEDS compared to healthy subjects, and whether a cognitive task can influence ventilation control differently in subjects with hEDS than in healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impairment of lung volume perception and breathing control in hypermobile Ehlers-Danlos syndrome.
Hakimi A, Bergoin C, De Jesus A, Hermand E, et al · · 2024 · cited 1× · PMID 38582758 · DOI 10.1038/s41598-024-58890-2

Verify or expand the search:

Other recruiting trials for Hypermobile Ehlers-Danlos Syndrome

Currently open trials in the same condition.

NCT05212129 — Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome · NA · recruiting

Other Hakimi Adrien trials

Trials by the same sponsor.

NCT04680793 — Effects of a Multidisciplinary Outpatient Rehabilitation Program in Patients With Ehlers-Danlos Syndrome. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05000151 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hakimi Adrien
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05000151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing